Gelonghui October 11th | Zhejiang East-Asia Pharmaceutical (605177.SH) announced that, according to the company's global strategy development, industrial layout needs, the company intends to appoint Mr. Chi Zhengming as a strategic and development consultant to provide advisory services for the company's overall development goals, development strategy, operational strategy, etc. And signed a "Strategic and Development Consultant Agreement" with Mr. Chi Zhengming, with a term of three years, from October 11, 2024 to October 10, 2027, with an annual remuneration of 1.3 million yuan for the strategic and development consultant (including tax).

Mr. Chi Zhengming is a shareholder of the company, a significant shareholder, holding more than 5% of the company's shares, and Mr. Chi Cheng, the father of the company's actual controller, chairman, general manager, and directly and indirectly holding more than 5% of the company's shares, have a father-son relationship. According to the relevant regulations of the Shanghai Stock Exchange Stock Listing Rules, Mr. Chi Zhengming is a related natural person of the company, and the "Strategic and Development Consultant Agreement" signed by the company and Mr. Chi Zhengming constitutes a related party transaction.